CYP2C19 and Stroke: Approximately 45% of the participants had one LOF allele (IM) and 16% of the participants had two LOF alleles (PM); (2) The 1-year MACCE-free survival rates were similar in the PM group compared to the NM + RM group or IM group; (3) In patients with AMI, the 1-year MACCE rates as well as the incidence of stroke, were significantly higher in the PM subgroup compared to the NM + RM subgroup or IM subgroup; (4) CYP2C19 poor metabolizer was a strong predictor for MACCE in patients presenting with AMI.